Lee Sul Ra, Jeong Kyung Hwan
Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
Electrolyte Blood Press. 2012 Dec;10(1):12-7. doi: 10.5049/EBP.2012.10.1.12. Epub 2012 Dec 31.
Cardio-renal syndrome (CRS) is a frequent and life-threatening syndrome. It is a disorder of the heart and kidneys in which acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Acute kidney injury (AKI) is strongly associated with increased morbidity and mortality in patients with CRS. Early detection of renal dysfunction is not possible using the traditional marker, serum creatinine, and therefore efforts to explore possible biomarkers for early detection of AKI are being made. Apart from predicting AKI, several biomarker studies also identified predictors for poor prognosis such as the need for renal replacement therapy (RRT) or death. It is possible that biomarkers can become risk factors in an improvement of clinical outcomes of CRS. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with renal dysfunction and the treatment for this disease can be modified based on cardiac biomarkers. In addition to natriuretic peptides, which are established cardiac markers, several new biomarkers have been identified and may play important roles in CRS. In this review, we will briefly summarize the literature on novel renal and cardiac biomarkers and discuss their potential roles in the clinical outcome of CRS.
心肾综合征（CRS）是一种常见且危及生命的综合征。它是一种心脏和肾脏的疾病，其中一个器官的急性或慢性功能障碍可能会诱发另一个器官的急性或慢性功能障碍。急性肾损伤（AKI）与CRS患者发病率和死亡率的增加密切相关。使用传统标志物血清肌酐无法早期检测肾功能障碍，因此人们正在努力探索可能用于早期检测AKI的生物标志物。除了预测AKI外，一些生物标志物研究还确定了诸如需要肾脏替代治疗（RRT）或死亡等不良预后的预测指标。生物标志物有可能成为改善CRS临床结局的危险因素。心血管疾病（CVD）是肾功能不全患者发病和死亡的主要原因，这种疾病的治疗可以根据心脏生物标志物进行调整。除了作为既定心脏标志物的利钠肽外，还发现了几种新的生物标志物，它们可能在CRS中发挥重要作用。在本综述中，我们将简要总结关于新型肾脏和心脏生物标志物的文献，并讨论它们在CRS临床结局中的潜在作用。
